RT Journal Article
SR Electronic
T1 A Longitudinal Seroepidemiology Study to Evaluate Antibody Response to SARS-CoV-2 Virus and Vaccination in Children in Calgary, Canada from July 2020 to April 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.02.22281665
DO 10.1101/2022.11.02.22281665
A1 Emily J. Doucette
A1 Joslyn Gray
A1 Kevin Fonseca
A1 Carmen Charlton
A1 Jamil N. Kanji
A1 Graham Tipples
A1 Susan Kuhn
A1 Jessica Dunn
A1 Payton Sayers
A1 Nicola Symonds
A1 Guosong Wu
A1 Stephen B Freedman
A1 James D. Kellner
A1 the Alberta COVID-19 Childhood Cohort (AB3C) Study Team
YR 2022
UL http://medrxiv.org/content/early/2022/11/05/2022.11.02.22281665.abstract
AB Background Measurement of SARS-CoV-2 antibody seropositivity is important to accurately understand exposure to infection and/or vaccination in specific populations.Methods Children with or without prior SARS-CoV-2 infections, was enrolled in Calgary, Canada in 2020. Venous blood was sampled 4 times from July 2020 to April 2022 for SARS-CoV-2 nucleocapsid and spike antibodies. Demographic and clinical information was obtained including SARS-CoV-2 testing results and vaccination records.Results 1035 children were enrolled and 88.9% completed all 4 visits; median age 9 years (IQR: 5,13); 519 (50.1%) female; and 815 (78.7%) Caucasian. Before enrollment, 118 (11.4%) had confirmed or probable SARS-CoV-2. By April 2022, 39.5% of previously uninfected participants had a SARS-CoV-2 infection. Nucleocapsid antibody seropositivity declined to 16.4% after more than 200 days after diagnosis. Spike antibodies remained elevated in 93.6% of unvaccinated children after more than 200 days after diagnosis. By April 2022, 408 (95.6%) children 12 years and older had received 2 or more vaccine doses, and 241 (61.6%) 5 to 11 year-old children had received 2 vaccine doses. At that time, all 685 vaccinated children had spike antibodies, compared with 94/176 (53.4%) of unvaccinated children.Conclusions In our population, after the first peak of Omicron variant infections and introduction of COVID-19 vaccines for children, all vaccinated children had SARS-CoV-2 spike antibodies, in contrast to 53.4% of unvaccinated children. It is not yet known whether a high level of seropositivity at a point in time indicates sustained population-level protection against SARS-CoV-2 transmission or severe COVID-19 outcomes in children.Summary By April 2022, all vaccinated children with or without acquired SARS-CoV-2 infections had spike antibodies, compared with just over one-half of unvaccinated children. It’s not known whether overall seropositivity level in a population indicates sustained protection against severe COVID-19 outcomes.Competing Interest StatementJDK has been an investigator on research projects funded by GlaxoSmithKline, Merck, Moderna, and Pfizer. All funds have been paid to his institute, and he has not received any personal payments. JD has been an investigator on a research project funded by Moderna. All funds have been paid to her institute, and she has not received any personal payments. All other authors declare no competing interests.Funding StatementFunding for the AB3C Study was provided by the Government of Alberta and the Alberta Children's Hospital Research Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received approval from the University of Calgary Conjoint Health Research Ethics Board (CHREB)(REB20-0480).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.